Liver biopsy is not routinely performed in treated chronic hepatitis B. Liver stiffness
measurement has been validated for noninvasive liver fibrosis assessment in pretreatment …

Noninvasive methods are increasingly used for the assessment of liver fibrosis. Two
categories of markers include serum-based markers (biologic properties) or ultrasound and …

Background The use of interferon-free direct-acting antiviral agents (DAAs) is associated
with a rapid short-term decrease in liver stiffness in chronic hepatitis C-infected patients with …

Abstract Background & Aims Several studies have shown that new direct‐acting antivirals
maintain their efficacy in liver transplant (LT) recipients with severe hepatitis C virus (HCV) …

Chronic liver disease affects 185 million population worldwide. It encompasses a
heterogenous disease spectrum, but all can lead to the development of liver fibrosis. The …

ABSTRACT Background & Aims: Liver stiffness (LS) measurement by Transient
Elastography (TE) has been widely accepted as a tool for fibrosis assessment. The aim of …

Abstract Background and Aim Patients with chronic hepatitis C (CHC) treated with direct‐
acting antivirals (DAAs) are still at risk for developing hepatocellular carcinoma (HCC) even …

Background Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus
(HCV)‐infected patients with compensated advanced chronic liver disease (cACLD) after the …

Staging fibrosis accurately has always been a challenge in viral hepatitis and other liver
diseases. Liver biopsy is an imperfect gold standard due to its intra and interobserver …

Liver fibrosis is the common pathway from various chronic liver diseases and its progression
leads to cirrhosis which carries a significant risk for the development of portal hypertension …